ESMO 2018 Congress

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.

Nonadherence to Tamoxifen Higher Than Reported Among Premenopausal Patients With Breast Cancer

Nonadherence to Tamoxifen Higher Than Reported Among Premenopausal Patients With Breast Cancer

Assessment of a subgroup of a cohort study revealed that many patients undergoing tamoxifen therapy for early-stage breast cancer do not adhere to their prescribed treatment, even though they claim adherence on patient surveys.

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

An analysis of pooled data from 4 randomized controlled clinical trials revealed that male and female patients experience different chemotherapy side effects and at different severities, according to a poster presented at ESMO 2018 Congress.

Many Breast Cancer Survivors' Desire for Pregnancy Changes After Treatment

Many Breast Cancer Survivors' Desire for Pregnancy Changes After Treatment

Researchers surveyed 60 breast cancer survivors to determine if their desire to achieve pregnancy had changed after completing treatment. These findings were presented at ESMO 2018 Congress.

Shorter Trastuzumab Course Achieves Similar DFS, Less Cardiac Toxicity in HER2+ Breast Cancer

Shorter Trastuzumab Course Achieves Similar DFS, Less Cardiac Toxicity in HER2+ Breast Cancer

Study findings presented at ESMO 2018 Congress revealed the effect of a shorter, 9-week course of trastuzumab on disease-free survival (DFS) and cardiac toxicity in women with HER2-positive breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs